AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of ... - MarketWatch (press release) PDF Print
MarketWatch (press release)... its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma (RCC).

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.